10.22.26 -- [For Biotech] Build Smarter Oncology Trials

Running complex trials on a lean budget? See how adaptive designs, decentralized models, and early real-world evidence help emerging drug developers plan globally and get therapies to patients faster.

Trials that look good on paper often stall at the site. Learn how involving sites early in study design cuts delays and keeps early-phase cancer studies delivering faster, more predictable trial outcomes.

A strong molecule is no longer enough. Learn how trial strategy and operational readiness can help your cancer therapy reach patients faster.

Oncology is moving to earlier treatment. Learn about the conversation highlights from ASCO and EHA 2026 focusing on designing faster, earlier-line trials that are progressing drug development.

As a full-service oncology CRO, we are dedicated to supporting biotech and emerging biopharma companies through every phase of development. Our extensive oncology expertise coupled with an end-to-end approach helps accelerate your clinical programs, giving you the confidence to bring breakthrough treatments to patients.

Dr. Kyle Bryan, Chief Medical Officer and board-certified expert in hematology and medical oncology shares valuable insights about how biotech is shaping clinical research, emphasizing the critical role of early engagement and the importance of forming the right partnerships to help sponsors harness medical and operational expertise.